Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-04-08
1995-11-14
Warden, Jill
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530327, 530409, 530825, C07K 708, C07K 14195, A61K 3810, A61K 3908
Patent
active
054666724
ABSTRACT:
Methods for treating cancer are described, including methods for treating colon and pancreatic cancer. Bacterial toxins and portions of bacterial toxins are employed as both diagnostic and therapeutic agents.
REFERENCES:
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4894443 (1990-01-01), Greenfield et al.
patent: 4962188 (1990-10-01), Frankel
patent: 5087616 (1992-02-01), Myers et al.
S. Donta et al., "Differential Effects of Clostridium difficile Toxins on Tissue-Cultured Cells," J. Clin. Microbiol. 15:1157 (1982).
C. Fiorentini et al., "Effects of Clostridium Difficile Toxins A and B on Cytoskeleton Organization in HEp-2 Cells: A Comparative Morphological Study," Toxicon 27:1209 (1991).
H. Krivan and T. Wilkins "Purification of Clostridium difficle Toxin A by Affinity Chromatography on Immobilized Thyroglobulin," Infect. Immun. 55:1873 (1987).
V. M. Kushnaryov et al., "Reversibility of Action of Clostridium Difficile Toxin A on Cho Cells and Intermediate Filaments in Nuclei," Proc. 46th Ann. Meeting Electron Microscopy Soc. Amer., 1988, p. 134.
A. Lima et al, "Clostridium Difficile Toxin A Interactions with Mucus and Early Sequential Histopathologic Effects in Rabbit Small Intestine," Laboratory Investigation 61:419 (1989).
A. Lima et al., "Effects of Clostridium difficile Toxins A and B in Rabbit Small and Large Intestine in Vivo and on Cultured Cells in Vitro," Infect. Immun. 56:582 (1988).
S. W. Rothman et al., "Differential Cytotoxic Effects of Toxins A and B Isolated from Clostridium difficile", Infect. Immun. 46:324 (1984).
J. Torres et al., "Sensitivity in Culture of Epithelial Cells from Rhesus Monkey Kidney and Human Colon Carcinoma to Toxins A and B from Clostridium Difficile," Toxicon 30:419 (1992).
Boring et al., Cancer Statistics, Cancer J. Clin. 42:19 (1992).
Macdonald et al., "5-Fluorouracil, Adriamycin, and Mitomycin-C (FAM) Combination Chemotherapy in the Treatment of Advanced Gastric Cancer," Cancer 44:42 (1979).
Gerlach et al., "Multidrug Resistance," Cancer Surv. 5:25 (1986).
Goldie and Coldman, "The Genetic Origin of Drug Resistance in Neoplasms: Implications for Systemic Therapy," Cancer Res. 44:3643 (1984).
Gottesman and Pastan, "Resistance to Multiple Chemotherapeutic Agents in Human Cancer Cells," Trends Pharm. Sci. 9:54 (1988).
Fischerman et al., "Survival among patients with Liver Mestastases from Cancer of the Colon and Rectum," Scand. J. Gastroent. Suppl. 37:111 (1976).
Anai et al., "Sensitivity Test for 5-Fluorouracil and Its Analogues, 1-(2-Tetrahydrofuryl)-5-Fluorouracil, Uracil/1-(2-Tetrahydrofuryl)-5-Fluorouracil (4:1) and 1-Hexylcarbamoyl-5-Fluoroacil, Using the Subrenal Capsule Assay," Oncology 45:144 (1988).
Lyerly et al., "Clostridium difficile: Its Disease and Toxins," Clin. Microbiol. Rev. 1:1 (1988).
Dove et al., "Molecular Characterization of the Clostridium difficile Toxin A Gene," Infect. Immun. 58:480 (1990).
Fiorentini and Thelestam, "Clostridium Difficile Toxin A and its Effects on Cells," Toxicon 29:543 (1991).
Kushnaryov and Sedmak, "Effect of Clostridium difficile Enterotoxin A on Ultrastructure of Chinese Hamster Ovary Cells," Infect. Immun. 57:3914 (1989).
Kushnaryov et al., "Actin and Iamin Comprised Filaments in the Nuclei of Chinese Hamster Ovary Cells Affected with Clostridium difficile Enterotoxin A," Cytobios 64:181 (1990).
Fiorentini et al., "Interaction of Clostridium difficile Toxin A with Cultured Cells: Cytoskeletal Changes and Nuclear Polarization," Infect. Immun. 58:2329 (1990).
Kushnaryov et al., "Cytotoxicity of Clostridium difficile Toxin A for Human Colonic and Pancreatic Carcinoma Cell Lines .sup.1," Cancer Res. 52:5096 (1992).
Redlich et al., "Selective Cytotoxicity of Clostridium difficile Enterotoxin A for Cancer Cell Lines of Gastrointestinal Tract Origin," Proc. Am. Assoc. Cancer Res. (1992).
Wren et al., "Antigenic Cross-Reactivity and Functional Inhibition by Antibodies to Clostridium difficile Toxin A, Streptococcus Mutans Glucan-Binding Protein, and a Synthetic Peptide," Infect. Immun. 59:3151 (1991).
V. Kushnaryov et al., "Cytotoxicity of Clostridium Difficile Entertoxin A: Unusual Intranuclear Structures in Cho Cells," Abstracts, P13.3.12, Fourth International Congress of Cell Biology, Montreal, Quebec, Canada, Aug. 14-19, 1988.
V. Ling, "P-Glycoprotein-Mediated Multidrug Resistance to Cancer Chemotherapy," Advances in Oncol. 9:3 (1993).
N. Sullivan et al., "Purification and Characterization of Toxins A and B of Clostridium difficile," Infect. Immun. 35:1032 (1982).
S. Donta and S. Shaffer, "Effects of Clostridium difficile Toxin on Tissue-Cultured Cells," J. Infect. Diseases 141:218 (1980).
Grossberg Sidney E.
Kushnaryov Vladimir M.
Redlich Philip N.
Sedmak J. James
Ophidian Pharmaceuticals Inc.
Salata Carol A.
Warden Jill
LandOfFree
Therapeutic use of clostridium difficile toxin A does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic use of clostridium difficile toxin A, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use of clostridium difficile toxin A will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1220973